Chong Kun Dang Pharmaceutical (185750) — Cash Flow Quality Index
Chong Kun Dang Pharmaceutical (185750) has a Cash Flow Quality Index of 1.07x as of September 2025. Operating cash flow of ₩21.45 Billion exceeds net income of ₩20.10 Billion, indicating high earnings quality where cash backs reported profits. Explore Chong Kun Dang Pharmaceutical (185750) long-term investment share to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Chong Kun Dang Pharmaceutical Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Chong Kun Dang Pharmaceutical across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Chong Kun Dang Pharmaceutical tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Chong Kun Dang Pharmaceutical (2016–2024)
Year-by-year earnings quality comparison for Chong Kun Dang Pharmaceutical. For live market cap and the full company financial profile, see Chong Kun Dang Pharmaceutical stock valuation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.59x | ₩64.29 Billion | ₩109.07 Billion | ▼ -61.3% |
| 2023 | 1.52x | ₩318.16 Billion | ₩208.86 Billion | ▲ +79.9% |
| 2022 | 0.85x | ₩67.73 Billion | ₩79.98 Billion | ▲ +158.7% |
| 2021 | 0.33x | ₩12.90 Billion | ₩39.42 Billion | ▼ -71.2% |
| 2020 | 1.14x | ₩104.32 Billion | ₩91.63 Billion | ▼ -20.6% |
| 2019 | 1.43x | ₩77.29 Billion | ₩53.88 Billion | ▲ +42.7% |
| 2018 | 1.01x | ₩42.63 Billion | ₩42.40 Billion | ▼ -33.8% |
| 2017 | 1.52x | ₩81.67 Billion | ₩53.81 Billion | ▲ +7.6% |
| 2016 | 1.41x | ₩57.79 Billion | ₩40.95 Billion | — |